A safety and efficacy study of SCH 503034 [boceprevir] in previously untreated subjects with chronic hepatitis C infected with genotype 1.

Trial Profile

A safety and efficacy study of SCH 503034 [boceprevir] in previously untreated subjects with chronic hepatitis C infected with genotype 1.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HCV SPRINT-1; SPRINT-1
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 04 Jul 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 09 Aug 2010 Results were published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top